Scholarlink

<p>Metal-based compounds have emerged as a promising class of potential antibiotics exhibiting high hit-rates against critical bacterial pathogens while not displaying higher toxicity than organic compounds. Here, we describe the exploration of novel, non-toxic, Gram-positive acting platinum-based antibacterial agents with high activity. Structure-activity relationship (SAR) studies revealed that the simplest scaffold showed the best antibacterial properties. Mode of action studies showed that lead compound <b>Pt1</b> akin to the structurally similar chemotherapeutic cisplatin, causes reduced DNA staining, visible nucleoid compaction, and activation of DNA damage repair responses. Importantly, we show that <b>Pt1</b> interacts with and damages DNA directly, resulting in DNA strand breaks and fragmentation. <b>Pt1</b> activity can be reduced by hydroxyl radical scavengers, suggesting that <b>Pt1</b> possesses a multimodal mechanism. In line with this observation, no resistance development to <b>Pt1</b> was observed. Finally, we demonstrate the in vivo activity of <b>Pt1</b>, which significantly reduced the bacterial load in a murine <i>S. aureus</i> skin infection model. These findings shed light on the SAR and antibacterial mode of action of a novel class of platinum metalloantibiotics, validate their in vivo efficacy, and pave the way for further exploration of platinum compounds as novel antibiotic drug candidates.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A platinum butterfly effect: small changes turn an anticancer drug into a non-toxic metalloantibiotic with in vivo efficacy

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月8日

查看全文
  • Çağrı Özsan,
  • Ann-Britt Schäfer,
  • Abdul Akhir,
  • Obed Akwasi Aning,
  • Sofia Fulgencio,
  • Rahul Maitra,
  • Rupa Rani,
  • Deepanshi Saxena,
  • Fredrik Westerlund,
  • Sidharth Chopra,
  • Michaela Wenzel,
  • Angelo Frei

摘要

Metal-based compounds have emerged as a promising class of potential antibiotics exhibiting high hit-rates against critical bacterial pathogens while not displaying higher toxicity than organic compounds. Here, we describe the exploration of novel, non-toxic, Gram-positive acting platinum-based antibacterial agents with high activity. Structure-activity relationship (SAR) studies revealed that the simplest scaffold showed the best antibacterial properties. Mode of action studies showed that lead compound Pt1 akin to the structurally similar chemotherapeutic cisplatin, causes reduced DNA staining, visible nucleoid compaction, and activation of DNA damage repair responses. Importantly, we show that Pt1 interacts with and damages DNA directly, resulting in DNA strand breaks and fragmentation. Pt1 activity can be reduced by hydroxyl radical scavengers, suggesting that Pt1 possesses a multimodal mechanism. In line with this observation, no resistance development to Pt1 was observed. Finally, we demonstrate the in vivo activity of Pt1, which significantly reduced the bacterial load in a murine S. aureus skin infection model. These findings shed light on the SAR and antibacterial mode of action of a novel class of platinum metalloantibiotics, validate their in vivo efficacy, and pave the way for further exploration of platinum compounds as novel antibiotic drug candidates.